Aerie Pharmaceuticals (AERI) 10-Q2022 Q1 Quarterly report

Filed: 5 May 22, 6:37pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: administered, Africa, bifurcation, bottle, branch, Cayman, Chemical, China, CIS, Commonwealth, conclusion, confirmatory, confirmed, country, credit, deployed, developmental, East, embedded, endothelial, expended, external, fee, gained, host, Independent, India, inflow, instrument, intent, lab, lang, Latin, lead, licensee, Middle, minimum, modified, modify, mutual, NDA, Nonqualified, Oceania, pan, peter, prospective, protocol, randomized, refusal, remotely, repay, retrospective, SA, single, substantial, supplemental, therapy, tracked, treatable, vascular, VEGF, vehicle

Removed: Additionally, adhering, advanced, adversely, affecting, aim, aimed, analog, announced, anticipation, API, arranging, Asian, ballot, beta, Biden, bimatoprost, blocker, Brexit, capitalized, chain, choice, communicating, compare, contact, continuing, covering, created, decision, decline, decreasing, dedicated, delayed, delivering, Department, dispensing, disrupted, disruption, distancing, economically, economy, education, educational, eliminating, enacted, enjoined, equivalent, escalation, establishment, evolving, execution, experiencing, expire, extent, Favored, final, finalized, force, Ganfort, geographic, goal, hand, harbor, home, human, idle, implement, implementation, implemented, implementing, important, importation, impose, improve, increasing, indirectly, influence, initiated, interactively, intraperiod, Japanese, large, legislation, legislative, lowest, manner, maximal, Medicaid, medical, Mercury, methodology, Nation, negatively, negotiation, order, partner, passed, PGA, preparing, present, pricing, produced, profitably, progression, prostaglandin, protection, Protein, put, reaching, rebate, recent, referencing, reform, reimbursed, removing, repayment, requiring, response, resumed, SAR, sell, Simplifying, social, sought, speaker, stage, Statute, step, strain, strict, successful, successfully, surface, system, technological, tie, timolol, traditional, transition, treasury, Trump, ultimate, underlying, unit, unnecessary, valid, virtual, worldwide

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated AERI transcripts

AERI similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the filing of the Quarterly Report on Form 10-Q of Aerie Pharmaceuticals, Inc., a Delaware corporation (the “Company”), for the period ended March 31, 2022 (the “Report”), the undersigned, Raj Kannan, Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 6, 2022

/s/ RAJ KANNAN

Raj Kannan

Chief Executive Officer

(Principal Executive Officer)